Onconetix shares rise 21.34% in intraday after reverse stock split and acquisition target's humanoid robot joins Ericsson 6G trials.

jueves, 26 de marzo de 2026, 10:27 am ET1 min de lectura
ONCO--
Onconetix surged 21.34% in intraday trading, driven by its effective 1-for-5 reverse stock split to meet Nasdaq's minimum price requirements and news that its acquisition target, Realbotix, is participating in Ericsson's 6G trials.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios